Recently, Aetna, which is one of the largest insurance companies in the United States, announced it would reimburse PAs at 85 percent of the physician pay schedule. So what does this move mean for PAs? Michael Powe, vice president of health systems reimbursement policy for the American Academy of Physician Assistants, joins host Lisa Dandrea Lenell to look at the current reimbursement picture and how PAs can make sure they are being reimbursed for the care they provide. They also look at how this process could change in the future with healthcare reform.
Recent Developments in Medical Billing and Reimbursement for PAs

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Recently, Aetna, which is one of the largest insurance companies in the United States, announced it would reimburse PAs at 85 percent of the physician pay schedule. So what does this move mean for PAs? Michael Powe, vice president of health systems reimbursement policy for the American Academy of Physician Assistants, joins host Lisa Dandrea Lenell to look at the current reimbursement picture and how PAs can make sure they are being reimbursed for the care they provide. They also look at how this process could change in the future with healthcare reform.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolving Our View of the Coagulation Cascade and Stroke Management
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Personalizing Care Within the RCC Treatment Paradigm
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?